MX381048B - Composiciones y métodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos. - Google Patents

Composiciones y métodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.

Info

Publication number
MX381048B
MX381048B MX2014015715A MX2014015715A MX381048B MX 381048 B MX381048 B MX 381048B MX 2014015715 A MX2014015715 A MX 2014015715A MX 2014015715 A MX2014015715 A MX 2014015715A MX 381048 B MX381048 B MX 381048B
Authority
MX
Mexico
Prior art keywords
masp
inhibitory agent
disease
compositions
subject
Prior art date
Application number
MX2014015715A
Other languages
English (en)
Spanish (es)
Other versions
MX2014015715A (es
Inventor
Gregory A Demopulos
Hans-Wilhelm Schwaeble
Patrick Gray
Thomas Dudler
Original Assignee
Omeros Corp
Univ Leicester
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=49769678&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=MX381048(B) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Omeros Corp, Univ Leicester filed Critical Omeros Corp
Publication of MX2014015715A publication Critical patent/MX2014015715A/es
Publication of MX381048B publication Critical patent/MX381048B/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/10—Antimycotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P33/00—Antiparasitic agents
    • A61P33/14—Ectoparasiticides, e.g. scabicides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/02—Antidotes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/40—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/21—Immunoglobulins specific features characterized by taxonomic origin from primates, e.g. man
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/31—Immunoglobulins specific features characterized by aspects of specificity or valency multispecific
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Epidemiology (AREA)
  • Pulmonology (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Microbiology (AREA)
  • Endocrinology (AREA)
  • Mycology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Rheumatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Virology (AREA)
  • Dermatology (AREA)
  • Transplantation (AREA)
  • Toxicology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pain & Pain Management (AREA)
MX2014015715A 2012-06-18 2013-06-18 Composiciones y métodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos. MX381048B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261661167P 2012-06-18 2012-06-18
PCT/US2013/046432 WO2013192240A2 (en) 2012-06-18 2013-06-18 Compositions and methods of inhibiting masp-1 and/or masp-2 and/or masp-3 for the treatment of various diseases and disorders

Publications (2)

Publication Number Publication Date
MX2014015715A MX2014015715A (es) 2016-02-05
MX381048B true MX381048B (es) 2025-04-01

Family

ID=49769678

Family Applications (4)

Application Number Title Priority Date Filing Date
MX2014015715A MX381048B (es) 2012-06-18 2013-06-18 Composiciones y métodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.
MX2020005700A MX2020005700A (es) 2012-06-18 2014-12-17 Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.
MX2019012909A MX2019012909A (es) 2012-06-18 2014-12-17 Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.
MX2024005899A MX2024005899A (es) 2012-06-18 2014-12-17 Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.

Family Applications After (3)

Application Number Title Priority Date Filing Date
MX2020005700A MX2020005700A (es) 2012-06-18 2014-12-17 Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.
MX2019012909A MX2019012909A (es) 2012-06-18 2014-12-17 Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.
MX2024005899A MX2024005899A (es) 2012-06-18 2014-12-17 Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.

Country Status (26)

Country Link
US (6) US20130344073A1 (cg-RX-API-DMAC7.html)
EP (5) EP4119577A3 (cg-RX-API-DMAC7.html)
JP (6) JP6445972B2 (cg-RX-API-DMAC7.html)
KR (4) KR20220100997A (cg-RX-API-DMAC7.html)
CN (4) CN118924900A (cg-RX-API-DMAC7.html)
AU (3) AU2013277309B2 (cg-RX-API-DMAC7.html)
BR (1) BR112014031522A2 (cg-RX-API-DMAC7.html)
CA (2) CA2875567C (cg-RX-API-DMAC7.html)
CL (2) CL2014003455A1 (cg-RX-API-DMAC7.html)
CY (1) CY1124234T1 (cg-RX-API-DMAC7.html)
DK (1) DK2861246T3 (cg-RX-API-DMAC7.html)
ES (1) ES2864857T3 (cg-RX-API-DMAC7.html)
HR (1) HRP20210559T1 (cg-RX-API-DMAC7.html)
HU (1) HUE053727T2 (cg-RX-API-DMAC7.html)
IL (2) IL236327B (cg-RX-API-DMAC7.html)
IN (1) IN2015KN00015A (cg-RX-API-DMAC7.html)
LT (1) LT2861246T (cg-RX-API-DMAC7.html)
MX (4) MX381048B (cg-RX-API-DMAC7.html)
NZ (1) NZ629473A (cg-RX-API-DMAC7.html)
PL (1) PL2861246T3 (cg-RX-API-DMAC7.html)
PT (1) PT2861246T (cg-RX-API-DMAC7.html)
RS (1) RS61755B1 (cg-RX-API-DMAC7.html)
RU (2) RU2019140356A (cg-RX-API-DMAC7.html)
SI (1) SI2861246T1 (cg-RX-API-DMAC7.html)
WO (1) WO2013192240A2 (cg-RX-API-DMAC7.html)
ZA (1) ZA201500094B (cg-RX-API-DMAC7.html)

Families Citing this family (61)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8937046B2 (en) 2008-09-22 2015-01-20 The Regents Of The University Of Colorado, A Body Corporate Modulating the alternative complement pathway
DK2694108T3 (en) 2011-04-08 2018-08-20 Univ Leicester METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
CA2865158C (en) 2012-02-24 2022-11-01 Chugai Seiyaku Kabushiki Kaisha Antigen-binding molecule for promoting disappearance of antigen via fc.gamma.riib
JP6774164B2 (ja) 2012-08-24 2020-10-21 中外製薬株式会社 マウスFcγRII特異的Fc抗体
US9217042B2 (en) * 2012-10-23 2015-12-22 Abbott Cardiovascular Systems Inc. Method of reducing MACE in diabetic patients subsequent to stent placement
CA2906096C (en) 2013-03-15 2022-03-15 Omeros Corporation Methods of generating bioactive peptide-bearing antibodies and compositions comprising the same
US20140363433A1 (en) 2013-03-15 2014-12-11 Omeros Corporation Methods of Generating Bioactive Peptide-bearing Antibodies and Compositions Comprising the Same
SG11201508170TA (en) 2013-04-02 2015-11-27 Chugai Pharmaceutical Co Ltd Fc REGION VARIANT
US20160053023A1 (en) * 2013-04-09 2016-02-25 Annexon, Inc. Methods of treatment for neuromyelitis optica
EP3003372B1 (en) 2013-06-07 2019-10-09 Duke University Inhibitors of complement factor h
SG11201510316UA (en) 2013-07-09 2016-01-28 Annexon Inc Anti-complement factor c1q antibodies and uses thereof
RS61351B1 (sr) 2013-10-17 2021-02-26 Omeros Corp Postupci za lečenje stanja udruženih sa aktivacijom komplementa zavisnom od masp-2
US10155983B2 (en) 2014-03-31 2018-12-18 Machaon Diagnostics, Inc. Method of diagnosis of complement-mediated thrombotic microangiopathies
AU2015269348C1 (en) * 2014-06-05 2021-11-18 The Regents Of The University Of Colorado, A Body Corporate MAp44 polypeptides and constructs based on natural antibodies and uses thereof
PL3215527T3 (pl) 2014-11-05 2025-04-28 Annexon, Inc. Humanizowane przeciwciała przeciwko czynnikowi dopełniacza C1Q i ich zastosowanie
US10639307B2 (en) 2015-05-15 2020-05-05 Children's Medical Center Corporation Methods relating to the diagnosis and treatment of preeclampsia comprising administration of ADAMTS13 polypeptides
CA2987976A1 (en) * 2015-06-03 2016-12-08 Coyne Ip Holdings, Llc Methods for establishing threshold limits for a chemical or biological agent in a target species
AR106018A1 (es) * 2015-08-26 2017-12-06 Achillion Pharmaceuticals Inc Compuestos de arilo, heteroarilo y heterocíclicos para el tratamiento de trastornos médicos
WO2017035409A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic compounds for treatment of immune and inflammatory disorders
WO2017035405A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amino compounds for treatment of immune and inflammatory disorders
WO2017035401A1 (en) 2015-08-26 2017-03-02 Achillion Pharmaceuticals, Inc. Amide compounds for treatment of immune and inflammatory disorders
CN117398458A (zh) * 2015-11-09 2024-01-16 奥默罗斯公司 用于治疗与masp-2依赖性补体活化相关的病况的方法
FI3380518T3 (fi) 2015-11-24 2026-05-29 Annexon Inc Antikomplementtitekijä-C1Q:n Fab-fragmentteja ja niiden käyttöjä
CA3010593C (en) * 2016-01-05 2024-02-13 University Of Leicester Methods for inhibiting fibrosis in a subject in need thereof
NZ745531A (en) * 2016-03-31 2020-09-25 Omeros Corp Methods for inhibiting angiogenesis in a subject in need thereof
JOP20170154B1 (ar) * 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة
JOP20170170B1 (ar) 2016-08-31 2022-09-15 Omeros Corp صيغ لجسم مضاد تثبيطية لـ masp-2 بتركيز عالي ولزوجة منخفضة وأطقم، وطرق
CA3053818A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Aryl, heteroaryl, and heterocyclic pharmaceutical compounds for treatment of medical disorders
WO2018160891A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceutical, Inc. Pharmaceutical compounds for treatment of medical disorders
WO2018160892A1 (en) 2017-03-01 2018-09-07 Achillion Pharmaceuticals, Inc. Macrocyclic compounds for treatment of medical disorders
US11827717B2 (en) 2017-04-03 2023-11-28 Chugai Seiyaku Kabushiki Kaisha Anti-MASP-1 antibodies and methods of use
MA49960A (fr) * 2017-08-25 2021-06-02 Omeros Corp Formulations d'anticorps inhibiteurs de masp-2 hautement concentrées à faible viscosité, kits et méthodes de traitement de sujets souffrant d'un syndrome hémolytique atypique
EP4640703A3 (en) 2017-11-14 2026-04-08 Chugai Seiyaku Kabushiki Kaisha Anti-c1s antibodies and methods of use
MX2020010528A (es) * 2018-04-13 2020-11-06 Chugai Pharmaceutical Co Ltd Anticuerpos anti-componente de complemento y metodos de uso.
WO2019231935A1 (en) 2018-05-29 2019-12-05 Omeros Corporation Masp-2 inhibitors and methods of use
EP3836965A4 (en) * 2018-06-22 2022-04-20 Omeros Corporation Compositions and methods of inhibiting masp-2 for the treatment of various thrombotic diseases and disorders
WO2020051538A1 (en) 2018-09-06 2020-03-12 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
JP7443375B2 (ja) 2018-09-06 2024-03-05 アキリオン ファーマシューティカルズ, インコーポレーテッド 医学的障害の治療のための大環状化合物
WO2020069024A1 (en) 2018-09-25 2020-04-02 Achillion Pharmaceuticals, Inc. Morphic forms of complement factor d inhibitors
MX2021006930A (es) 2018-12-11 2021-11-17 Q32 Bio Inc Construcciones de proteínas de fusión para enfermedades asociadas al complemento.
CN113195472A (zh) 2018-12-17 2021-07-30 艾其林医药公司 用于治疗补体介导的病症的靶向给药
MX2021011507A (es) 2019-03-22 2021-12-15 Achillion Pharmaceuticals Inc Compuestos farmaceuticos para el tratamiento de trastornos mediados por complemento.
CA3139209A1 (en) * 2019-05-07 2020-11-12 Bayer Aktiengesellschaft Masp inhibitory compounds and uses thereof
CA3137649A1 (en) 2019-05-15 2020-11-19 Chugai Seiyaku Kabushiki Kaisha An antigen-binding molecule, a pharmaceutical composition, and a method
KR20220083737A (ko) * 2019-10-17 2022-06-20 애넥슨, 인코포레이티드 혈액 장애를 치료하기 위한 조성물 및 방법
AU2020395306B2 (en) 2019-12-04 2025-04-24 Omeros Corporation MASP-2 inhibitors and methods of use
CN115052862A (zh) 2019-12-04 2022-09-13 奥默罗斯公司 Masp-2抑制剂和使用方法
JP7699389B2 (ja) 2019-12-04 2025-06-27 オメロス コーポレーション Masp-2阻害剤および使用方法
BR112022010895A2 (pt) 2019-12-04 2022-09-06 Omeros Corp Composto, composição farmacêutica, e, método para tratar uma doença ou distúrbio associado à serina protease-2 associada à lectina de ligação ao manan
CN112237630A (zh) * 2020-02-21 2021-01-19 中国人民解放军军事科学院军事医学研究院 针对masp-2、冠状病毒n蛋白或其结合的物质在制备冠状病毒所致疾病药物中的应用
TWI867422B (zh) * 2020-03-06 2024-12-21 美商奥默羅斯公司 用於治療和/或預防流感病毒誘導的急性呼吸窘迫症候群、肺炎或者流感病毒感染的一些其它肺部表現的抑制masp-2的方法
IL300704A (en) 2020-08-18 2023-04-01 Omeros Corp Monoclonal antibodies, preparations and methods for detecting complement factor D
CN115215937B (zh) 2021-04-15 2023-05-26 上海麦济生物技术有限公司 抗人masp-2抗体及其制备方法和应用
CA3240483A1 (en) 2021-12-10 2023-06-15 Thomas Dudler Therapeutic antibodies that bind to the serine protease domain of masp-2 and uses thereof
US12486322B2 (en) 2021-12-13 2025-12-02 Annexon, Inc. Anti-complement factor C1q antibodies with single binding arms and uses thereof
CN114989259B (zh) * 2022-05-27 2023-06-09 成都佩德生物医药有限公司 一种小分子肽Ped4及应用
CN115125299A (zh) * 2022-08-09 2022-09-30 大连珍奥药业股份有限公司 Masp1在筛选预防和/或治疗心血管疾病的药物中的应用
JP2025541737A (ja) 2022-11-30 2025-12-23 オメロス コーポレーション Masp-2阻害物質としての縮合ピリミジン
EP4677366A1 (en) * 2023-03-03 2026-01-14 The City University Of New York Use of extracellular vesicles as biomarkers for age-related macular degeneration
US20250122225A1 (en) 2023-10-06 2025-04-17 Omeros Corporation Masp-2 inhibitors and methods of use
WO2026124436A1 (zh) * 2024-12-09 2026-06-18 舒泰神(北京)生物制药股份有限公司 Taci融合蛋白及其用途

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4331647A (en) 1980-03-03 1982-05-25 Goldenberg Milton David Tumor localization and therapy with labeled antibody fragments specific to tumor-associated markers
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US4676980A (en) 1985-09-23 1987-06-30 The United States Of America As Represented By The Secretary Of The Department Of Health And Human Services Target specific cross-linked heteroantibodies
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
US5211657A (en) 1988-11-07 1993-05-18 The United States Government As Represented By The Secretary Of The Department Of Health And Human Services Laminin a chain deduced amino acid sequence, expression vectors and active synthetic peptides
US5530101A (en) 1988-12-28 1996-06-25 Protein Design Labs, Inc. Humanized immunoglobulins
US5549910A (en) 1989-03-31 1996-08-27 The Regents Of The University Of California Preparation of liposome and lipid complex compositions
DE69030172T2 (de) 1990-01-26 1997-06-19 Immunomedics Inc Impfstoffe gegen Krebs und Infektionskrankheiten
JP3218637B2 (ja) 1990-07-26 2001-10-15 大正製薬株式会社 安定なリポソーム水懸濁液
JP2958076B2 (ja) 1990-08-27 1999-10-06 株式会社ビタミン研究所 遺伝子導入用多重膜リポソーム及び遺伝子捕捉多重膜リポソーム製剤並びにその製法
ATE199392T1 (de) 1992-12-04 2001-03-15 Medical Res Council Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5856121A (en) 1994-02-24 1999-01-05 Case Western Reserve University Growth arrest homebox gene
US6074642A (en) 1994-05-02 2000-06-13 Alexion Pharmaceuticals, Inc. Use of antibodies specific to human complement component C5 for the treatment of glomerulonephritis
US5741516A (en) 1994-06-20 1998-04-21 Inex Pharmaceuticals Corporation Sphingosomes for enhanced drug delivery
US5795587A (en) 1995-01-23 1998-08-18 University Of Pittsburgh Stable lipid-comprising drug delivery complexes and methods for their production
US5731168A (en) 1995-03-01 1998-03-24 Genentech, Inc. Method for making heteromultimeric polypeptides
US5738868A (en) 1995-07-18 1998-04-14 Lipogenics Ltd. Liposome compositions and kits therefor
RU2002113381A (ru) * 1999-12-02 2004-01-27 Дженс Христиан ДЖЕНСЕНИУС (DK) MASP-3, комплемент-связывающий фермент и его применение
SG98393A1 (en) 2000-05-19 2003-09-19 Inst Materials Research & Eng Injectable drug delivery systems with cyclodextrin-polymer based hydrogels
DE60307701T2 (de) * 2002-03-15 2007-10-11 Natimmune A/S Mannose-Bindungsprotein enthaltende pharmazeutische Zusammensetzungen
EP1531757B1 (en) 2002-07-19 2016-09-07 Omeros Corporation Biodegradable triblock copolymers, synthesis methods therefor, and hydrogels and biomaterials made there from
US7666627B2 (en) * 2002-08-08 2010-02-23 Targetex Kft. Folded recombinant catalytic fragments of multidomain serine proteases, preparation and uses thereof
AU2004216176B2 (en) * 2003-02-21 2008-04-03 Genentech, Inc. Methods for preventing and treating tissue damage associated with ischemia-reperfusion injury
WO2005005630A2 (en) * 2003-07-08 2005-01-20 Umc Utrecht Holding B.V. Therapeutic use of lpi, a staphylococcal lectin pathway inhibitor in inflammatory diseases
US7919094B2 (en) * 2004-06-10 2011-04-05 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
US8840893B2 (en) * 2004-06-10 2014-09-23 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
EP2465534B1 (en) * 2004-06-10 2017-03-29 Omeros Corporation Methods for treating conditions associated with MASP-2 dependent complement activation
CN100518905C (zh) * 2004-11-02 2009-07-29 浙江欧美环境工程有限公司 折返式电除盐器
KR20140053410A (ko) 2005-08-19 2014-05-07 아보트 러보러터리즈 이원 가변 도메인 면역글로불린 및 이의 용도
US7612181B2 (en) 2005-08-19 2009-11-03 Abbott Laboratories Dual variable domain immunoglobulin and uses thereof
KR101126423B1 (ko) * 2005-10-21 2012-07-11 카탈리스트 바이오사이언시즈, 인코포레이티드 보체 활성화를 억제하는 변형된 프로테아제
DK1991275T3 (en) * 2006-03-08 2014-12-08 Archemix Llc Complement aptamers AND ANTI-C5 AGENTS FOR USE IN THE TREATMENT OF EYE DISEASES
JP5537420B2 (ja) 2007-05-31 2014-07-02 ユニヴァーシティ オブ ワシントン 標的遺伝子の誘導性変異誘発
JP6223659B2 (ja) * 2008-11-10 2017-11-01 アレクシオン ファーマシューティカルズ, インコーポレイテッド 補体関連障害を処置するための方法および組成物
NZ597259A (en) * 2009-06-23 2014-04-30 Alexion Pharma Inc Bispecific antibodies that bind to complement proteins
CA2767755C (en) * 2009-07-17 2021-10-12 Rigshospitalet Inhibitors of complement activation
EP3150635A3 (en) * 2009-10-16 2017-06-21 Omeros Corporation Methods for treating disseminated intravascular coagulation by inhibiting masp-2 dependent complement activation
AU2011222883B2 (en) * 2010-03-05 2016-05-26 Omeros Corporation Chimeric inhibitor molecules of complement activation
US8795973B2 (en) * 2010-11-29 2014-08-05 University of Leceister Methods for identifying inhibitors of mannan-binding lectin associated serine protease (MASP) proteins and uses thereof
DK2694108T3 (en) * 2011-04-08 2018-08-20 Univ Leicester METHODS OF TREATING DISEASES ASSOCIATED WITH MASP-2 DEPENDENT COMPLEMENT ACTIVATION
NZ629675A (en) * 2012-04-06 2017-02-24 Omeros Corp Compositions and methods of inhibiting masp-1, masp-2 and/or masp-3 for treatment of paroxysmal nocturnal hemoglobinuria
JOP20170154B1 (ar) * 2016-08-01 2023-03-28 Omeros Corp تركيبات وطرق لتثبيط masp-3 لعلاج أمراض واضطرابات مختلفة

Also Published As

Publication number Publication date
EP4659763A2 (en) 2025-12-10
JP7839502B2 (ja) 2026-04-02
US20260049158A1 (en) 2026-02-19
HUE053727T2 (hu) 2021-07-28
JP2015521623A (ja) 2015-07-30
CL2014003455A1 (es) 2015-04-10
PL2861246T3 (pl) 2021-10-25
IN2015KN00015A (cg-RX-API-DMAC7.html) 2015-07-31
US20190127484A1 (en) 2019-05-02
EP4659763A3 (en) 2025-12-24
EP3878865A2 (en) 2021-09-15
IL261436B (en) 2021-08-31
JP2022084946A (ja) 2022-06-07
AU2013277309A1 (en) 2015-01-22
MX2020005700A (es) 2020-09-25
EP2861246A2 (en) 2015-04-22
CN118924900A (zh) 2024-11-12
DK2861246T3 (en) 2021-04-26
LT2861246T (lt) 2021-04-26
EP2861246B1 (en) 2021-01-20
MX2024005899A (es) 2024-05-30
WO2013192240A3 (en) 2014-07-03
CA3214532A1 (en) 2013-12-27
US20240254257A1 (en) 2024-08-01
CN104717975A (zh) 2015-06-17
KR20200116164A (ko) 2020-10-08
ZA201500094B (en) 2019-08-28
EP4119577A3 (en) 2023-11-08
IL236327A0 (en) 2015-02-26
US20260035483A1 (en) 2026-02-05
KR20220100997A (ko) 2022-07-18
EP2861246A4 (en) 2016-03-23
WO2013192240A2 (en) 2013-12-27
JP6445972B2 (ja) 2018-12-26
CL2016003297A1 (es) 2017-06-02
JP2024099699A (ja) 2024-07-25
AU2020202999A1 (en) 2020-05-28
ES2864857T3 (es) 2021-10-14
IL236327B (en) 2019-02-28
CN109908352A (zh) 2019-06-21
NZ728179A (en) 2021-12-24
CY1124234T1 (el) 2022-05-27
EP4119577A2 (en) 2023-01-18
RU2015101230A (ru) 2016-08-10
HK1209623A1 (zh) 2016-04-08
SI2861246T1 (sl) 2021-08-31
RU2019140356A (ru) 2020-01-27
KR102339315B1 (ko) 2021-12-15
AU2018204285B2 (en) 2020-02-27
US20220259325A1 (en) 2022-08-18
HRP20210559T1 (hr) 2021-05-14
AU2013277309B2 (en) 2018-03-29
IL261436A (en) 2018-11-04
US20130344073A1 (en) 2013-12-26
MX2014015715A (es) 2016-02-05
AU2020202999B2 (en) 2022-03-24
CA2875567A1 (en) 2013-12-27
EP3058951A1 (en) 2016-08-24
PT2861246T (pt) 2021-04-05
KR20200015952A (ko) 2020-02-13
MX2019012909A (es) 2020-12-10
KR20150031298A (ko) 2015-03-23
JP2019048881A (ja) 2019-03-28
CA2875567C (en) 2023-11-14
JP2026021601A (ja) 2026-02-10
EP3878865A3 (en) 2021-12-08
RS61755B1 (sr) 2021-05-31
JP2021006546A (ja) 2021-01-21
RU2709351C2 (ru) 2019-12-17
NZ629473A (en) 2017-02-24
BR112014031522A2 (pt) 2017-08-01
CN115040653A (zh) 2022-09-13
JP6771531B2 (ja) 2020-10-21

Similar Documents

Publication Publication Date Title
MX2024005899A (es) Composiciones y metodos para inhibir masp-1 y/o masp-2 y/o masp-3 para el tratamiento de varias enfermedades y trastornos.
EP4491229A3 (en) Coding rna administered into the suprachoroidal space in the treatment of ophtalmic diseases
EP2855435A4 (en) DENDRIMOUS AMINOAMIDE WITH SODIUM CHANNEL BLOCKER ACTIVITY FOR THE TREATMENT OF XEROPHTHALMIA AND OTHER MEASURED TIPS
EP3562514A4 (en) GENE THERAPY FOR THE TREATMENT OF WILSON'S DISEASE
CY1119420T1 (el) Νεες θεραπευτικες προσεγγισεις για θεραπεια ασθενειας parkinson
BR112018068538A2 (pt) composto, medicamento, uso de um composto, e, métodos para inibir monoacilglicerol lipase e para profilaxia ou tratamento de doença ou transtorno.
UA113165C2 (xx) Застосування комбінації баклофену і акампросату для лікування неврологічних захворювань та композиція, яка містить баклофен і акампросат
BR112015001847A2 (pt) composições e tratamento para doenças e distúrbios nos olhos
BR112016013109A2 (pt) anticorpos de anti-siglec-8 e métodos de seu uso
TN2017000119A1 (en) Indole carboxamides compounds useful as kinase inhibitors
EA201590654A1 (ru) Комбинация разагилина и придопидина для лечения нейродегенеративных нарушений, в частности болезни хантингтона
BR112015022597A2 (pt) partículas modificadoras da imunidade para o tratamento de inflamação
BR112015010663A2 (pt) formas de dosagem de ruxolitinib de liberação sustentada
EA201491606A1 (ru) Ингибиторы кинуренин-3-монооксигеназы, фармацевтические композиции и способы их применения
TR201816176T4 (tr) Histon deasetilaz 6 inhibitörleri olarak yeni bileşikler ve bunu içeren farmasötik bileşimler.
EA201491199A1 (ru) Наночастицы, включающие металлические материал и материал оксида гафния, композиция и ее применение
EP3818991A3 (en) Compositions and methods for treating diseases
JO3462B1 (ar) أجسام مضادة بشرية تجاه gfr?3 وطرق لاستخدامها
MX386256B (es) Derivados de acido oleanolico modificado en c4 para la inhibicion de il-17 y otros usos.
AR101740A1 (es) Terapia de combinación y composiciones
EA201390826A1 (ru) ПИРИМИДИНОНОВЫЕ СОЕДИНЕНИЯ ДЛЯ ПРИМЕНЕНИЯ В ЛЕЧЕНИИ ЗАБОЛЕВАНИЙ ИЛИ СОСТОЯНИЙ, ОПОСРЕДОВАННЫХ Lp-PLA
EA201590726A1 (ru) Лахинимод для уменьшения таламического поражения при рассеянном склерозе
EA201790563A8 (ru) Применение реслизумаба для лечения эозинофильной астмы со степенью тяжести от умеренной до тяжелой
MX2021006985A (es) Metodos para el tratamiento de la depresión.
GT201400155A (es) Nuevas formas y sales de un dihidropirrolo [1,2-c] imidazolilo, inhibidor de la aldosterona sintasa o aromatasa